Lumateperonum

Lumateperonum (antea: ITI-007) est antipsychotica atypicum et medicamentum ad therapiam schizophreniarum praescriptum^[1]. Virtutes suae ad systemata et serotonergicum et dopaminergicum et glutamatergicum spectant^[2].

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

Lumateperonum
Cognitores
ChemSpider	7997690
PubChem	9821941
DrugBank	DB06077
Natura chemica

Formula summarum	C ₂₄H ₂₈FN ₃O
Massa molaris	393.506 g/mol
Ad usum therapeuticum
Applicatio	per os
MedlinePlus	a620014 (Anglice)

Natura Lumateperoni

Natura chemica

Structura chemica Lumateperoni est 1-(4-Fluorophenylo)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyridino[3',4':4,5]pyrrolo[1,2,3-de]quinoxalino-8(7H)-yl)-1-butanonum. Massa molaris est 393.506 g/mol.

Pharmacodynamica

Receptorium	Lumateperoni affinitas ligandi, K_i (nM)^[3]	Actio
dopamini D₁	4.1
dopamini D₂	3.2	prae- et postsynapticum
serotonini 5-HT_2A	0.54
SERT	3.3

Lumateperonum receptoria D₂ postsynaptica inhibet, at etiam agonista praesynapticarum receptoriorum D₂ agit. Praeterea inhibitio receptoriorum serotonergicorum 5HT_2A descripta est.

Nexus interni

Haloperidolum

Notae

↑ Vyas P., Hwang B. J., Brašić J. R. (Feb 2020). An evaluation of lumateperone tosylate for the treatment of schizophrenia. 21. pp. 139-45
↑ Kumar B., Kuhad A., Kuhad A. (Dec 2018). "Lumateperone: a new treatment approach for neuropsychiatric disorders". Drugs of today 54 (12): 713-9
↑ https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php

[1] Vyas P., Hwang B. J., Brašić J. R. (Feb 2020). An evaluation of lumateperone tosylate for the treatment of schizophrenia. 21. pp. 139-45

[2] Kumar B., Kuhad A., Kuhad A. (Dec 2018). "Lumateperone: a new treatment approach for neuropsychiatric disorders". Drugs of today 54 (12): 713-9

[3] ttps://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php

[1]

[2]

[3]